Organisation paid for research Program year 2025 Source: CMS Open Payments

Start Mountain Region LLC

Neither a doctor nor a teaching hospital

Research payments

$5,793,930

638 payments

Through program year 2025, Start Mountain Region LLC is reported as receiving $5,793,930 in research payments, across 638 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $4,074,732 496
2024 Research $1,057,176 75
2023 Research $317,974 10
2022 Research $119,491 41
2021 Research $224,557 16

Breakdown

Who paid Research payments · program years 2021–2025
  1. Eli Lilly and Company $1,704,687 13 payments
  2. GlaxoSmithKline, LLC. $996,356 173 payments
  3. Genmab U.S., Inc. $955,354 99 payments
  4. Pfizer Inc. $578,545 79 payments
  5. BioNTech SE $406,816 89 payments
  6. Coherus Biosciences Inc. $380,560 42 payments
  7. Stemline Therapeutics Inc. $268,967 41 payments
  8. Janssen Research & Development, LLC $212,410 55 payments
  9. AbbVie, Inc. $170,086 25 payments
  10. MacroGenics, Inc. $56,290 15 payments
Studies the money was for Research payments · program years 2021–2025
  1. Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors $955,354 99 payments
  2. A First in Human Phase 1A and 1B Trial to Assess the Safety Tolerability and Preliminary Efficacy of Ly4170156 An Antibody Drug Conjugate Targeting Folate Receptor A Expressing Tumor Cells in Participants With Selected Advanced Tumors $884,627 2 payments
  3. A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmac $865,368 145 payments
  4. Bnt326-01 $406,816 89 payments
  5. A Phase 1A/1B Study of Ly3537982 in Patients With Kras G12c-Mutant Advanced Solid Tumors $381,291 5 payments
  6. A Phase 1A/1B Study of Ly3537982 in Patients With Kras G12c-Mutant Advanced Solid Tumors $273,697 2 payments
  7. A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer $268,967 41 payments
  8. Srf114-101 $253,037 38 payments
  9. An Openlabel Phase 1 Study to Investigate Sgnceacam5c in Adults With Advanced Solid Tumors $245,999 25 payments
  10. An Interventional Safety and Efficacy Phase 1B2 Openlabel Study to Investigate Tolerability PK and Antitumor Activity of Vepdegestrant Arv471pf07850327 An Oral Proteolysis Targeting Chimera in Combination With Pf07220060 in Participants Aged 18 Years and Older With Erher2 Advanced Or Metastatic Breast Cancer $189,963 25 payments
What the money was spent on Research payments · program years 2021–2025
  1. Other $56,290 15 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record